[Efficacy of the complex drug cytoflavin in the treatment of consequences of mild brain injury].
Sixty outpatients, aged 18-50 years, with mild cranial-brain trauma (brain concussion, mild brain injury), occurred 21-180 days before the enrollment in the study, were examined. Patients of the main group received cytoflavin in dose 425 mg, 2 tablets twice a day during 25 days, patients of the control group received aminalon in dose 500 mg, 2 tablets 3 times a day during 25 days. The therapeutic efficacy was assessed on days 1, 30 and 60 with the battery of neuropsychological scales. The efficacy and safety of cytoflavin in the monotherapy of patients with remote consequences of mild cranial-brain trauma was shown. The effect of cytoflavin was developed significantly more rapidly compared to aminalon. There were positive changes on scales of pain severity, psychoemotional disorders (anxiety, depression, asthenia), sleep quality, autonomic dysfunctions as well as in the performance on neurocognitive tests assessing memory, sustained attention, information processing speed, productivity. The duration of using analgesics and sedatives as add-on drugs was reduced significantly. The drug remained effective till the 60th day after the 30 day withdrawal. Side-effects of cytoflavin (the short-term rise of arterial pressure, insomnia and abdominalgia) did not last long and no additional treatment, withdrawal or reduction of cytoflavin dose was needed.
Skoromets
A A
AA
Pugacheva
E L
EL
D000293:Adolescent; D000328:Adult; D001930:Brain Injuries / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D004338:Drug Combinations; D005486:Flavin Mononucleotide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007290:Inosine Diphosphate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009536:Niacinamide / Q000009:adverse effects / Q000627:therapeutic use*; D013386:Succinates / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000627:therapeutic use
D004338:Drug Combinations; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005680:gamma-Aminobutyric Acid; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate